Spot on. The results are in. The company has increased its sales, which is great, but expenses related to the sales have accelerated more, it raised capital only in March and by now will be showing signs of depleting it. That capital was to advance the sales of the prime product, meanwhile the holy grail - 2RT sits on a shelf with a patent and no money to develop it or get it past trials. The gains have been had - harsh but true. And that is best case if there is no market correction in the meantime...........there will be at some point.
Spot on. The results are in. The company has increased its...
-
- There are more pages in this discussion • 142 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.23M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 18.0¢ | $13.23K | 73.51K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 49553 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| EYE (ASX) Chart |